Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
about
Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple SclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisThe single nucleotide variant rs12722489 determines differential estrogen receptor binding and enhancer properties of an IL2RA intronic regionDaclizumab for the treatment of multiple sclerosis.Innate lymphoid cells: major players in inflammatory diseases.Human CD56bright NK Cells: An Update.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Daclizumab: A Review in Relapsing Multiple Sclerosis.CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation.Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.Pharmacodynamic effects of daclizumab in the intrathecal compartment.Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.Perspective: Who dares, wins.Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.Daclizumab Therapy for Multiple Sclerosis.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis
P2860
Q26771459-23FD4AF2-BCD1-467B-BA38-BE4B247039E1Q28066677-731E121C-46A8-457E-A5AA-64ACEBDE19F0Q36289774-035FE660-1C77-4A79-974C-796C78CAEF0BQ38604207-B28DF19D-269E-4799-99E4-8D78E95A51D8Q38643190-9D4FD999-BF9B-4494-B3DE-575A8197E669Q38781384-FD5340B2-4152-43FB-B5DA-F3DF4DB59D25Q38918124-2D67BE5F-74D6-477E-B9AB-4734BAAEDC16Q38954794-AF306EEB-B3A4-4E51-BF15-B0FF852751F7Q39119839-DE44B26D-18C8-42AC-BA25-36C1FE8FE97CQ39140303-9FA59A9C-DD68-4FA2-8861-6EAC0FECFB75Q39668327-D404E442-AC1C-4087-9A28-06058B0C055DQ40044090-57549663-90F6-47E0-9443-481F22E1D7F5Q40962441-9424CC75-4358-4C38-9680-A55FB68BD473Q42264650-CBDEE428-B0C2-43E6-A936-43483D513455Q47102132-EB597239-53FA-445F-8D4F-1FD4DD75E2A5Q47379142-AA18BF28-CBC4-452B-8389-93FD5B4624C6Q47657261-A3BE3BF6-7DF3-4191-B845-ABF2C3F16268Q52319805-63DBADDE-012F-4112-8069-992E281E09BAQ55052878-E0C05014-4C03-4BFE-BE81-A25E73891D22Q57470698-5990157A-8DA3-48D4-8D13-C48409B871C5
P2860
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@ast
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@en
type
label
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@ast
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@en
prefLabel
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@ast
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@en
P2093
P2860
P356
P1476
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
@en
P2093
Andrew Blake
Bibiana Bielekova
Elena Romm
Paige Winokur
Tianxia Wu
Yen Chih Lin
P2860
P304
P356
10.1002/ACN3.181
P577
2015-04-07T00:00:00Z